Isakoff, Steven J. http://orcid.org/0000-0002-6677-1014
Said, Maya R.
Kwak, Agnes H.
Glieberman, Eva
O’Rourke, Emily A.
Stroiney, Amanda
Spring, Laura M.
Moy, Beverly
Bardia, Aditya
Horick, Nora
Peppercorn, Jeffrey M.
Funding for this research was provided by:
Outcomes4Me Inc
Article History
Received: 9 August 2022
Accepted: 18 March 2023
First Online: 27 April 2023
Declarations
:
: Jeffrey M. Peppercorn has received research funding from Outcomes4Me Inc., consulted for Abbott Labs and reports a family member employed by GlaxoSmithKline. Maya R. Said is an employee and has ownership interest in Outcomes4Me Inc. Eva Glieberman is an employee of Outcomes4Me Inc. Emily A. O’Rourke is an employee and has ownership interest in Outcomes4Me Inc. Amanda Stroiney is an employee and has ownership interest in Outcomes4Me Inc. Aditya Bardia has received research funding from Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics, Gilead, Daiichi Pharma, Astra Zeneca, and Eli Lilly, and has consulted for Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics, Gilead, Sanofi, Daiichi Pharma, Astra Zeneca, Phillips, Eli Lilly, Foundation Medicine. Laura Spring has received research funding from Merck, Phillips, and Eli Lilly, and has consulted for Novartis and Puma. Steven J Isakoff has received research funding from Abbvie, Astra Zeneca, Genentech, Merck, and OncoPep, and has consulted for Seattle Genetics, Novartis, Paxman, and Puma, and reports a family member employed by Merus NV. Agnes H. Kwak, Beverly Moy, and Nora Horick declare no relevant competing financial interests.
: Approval was obtained from the Dana Farber Harvard Cancer Center Institute Institutional Review Board. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study.